
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is a promising company with a positive outlook due to its innovative and effective product candidates, especially Izicopan and vilobelimab, for the treatment of autoimmune and inflammatory diseases. The company's potential for high sales, improved safety and convenience, and potential partnerships make it a strong contender in the biopharmaceutical market. The setbacks faced by its competitor, Tavneos, also give InflaRx a potential advantage. The company's ongoing discussions with regulatory agencies and positive updates suggest a positive potential for success, making it a compelling investment opportunity.
Bears say
InflaRx is facing significant challenges with its flagship product, Tavneos, due to safety concerns and allegations of data integrity issues. Moreover, the company's lack of visibility on ROW sales adds to the uncertainty around its financial performance. Despite having a potentially promising pipeline and a unique mechanism of action, InflaRx faces numerous risks and hurdles in successfully developing and commercializing its products.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares